Vectura’s development and formulation expertise is evidenced by numerous accomplishments including seven marketed therapies, such as Novartis’ recently approved Seebri® Breezhaler® for the treatment of COPD Vectura and its partners announce positive Phase II date with combination treatment QVA149 and the start of Phase III trials with NVA237 Vectura’s approach to product development is driven by innovative and enabling formulation and inhalation device technologies We are also keen to protect the flexibility and informality of the Company as we grow Register to our news alert and receive latest updates on news and events